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Abstract
Background: A reliable early marker is required for diag-
nosis of cobalamin deficiency. We calculated an appropriate
holotranscobalamin (HoloTC) cut-off point for identifying
cobalamin deficiency using an immunoenzymatic assay.
Methods: Determination of the cut-off threshold and corre-
lation between HoloTC and the other diagnostic parameters
routinely used for vitamin B12 deficiency wtotal vitamin B12
(tB12), folate, homocysteinex were measured in 250 routine
blood specimens from 107 men (mean age 59.0"18.8 years)
and 143 women (mean age 54.2"23.1 years). The inclusion
criterion was serum tB12 concentration F221 pmol/L.
Results: Analytical performance results agreed with those
reported by others. A weak correlation (Rs0.42) was found
between HoloTC and tB12. A 40 pmol/L cut-off threshold
was chosen for HoloTC and the associated sensitivity and
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specificity was 0.86 and 0.66, respectively. Out of 250 tested
samples, 126 showed tB12 concentrations 139–221 pmol/L
(gray zone, GZ) and 124 had tB12 concentrations
-139 pmol/L (low, L). Values less than the cut-off for
HoloTC were present in 68.2% and 37.9% of cases in the
GZ and L group, respectively (p-0.01), and in 53.2% of
subjects.
Conclusions: Our results confirmed the analytical reliability
of the AxSYM HoloTC assay. The method is adequate for
routine use and a cut-off threshold of 40 pmol/L is appro-
priate for assessing cobalamin deficiency in populations with
reduced tB12 values.
Clin Chem Lab Med 2010;48:249–53.
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Introduction
Vitamin B12 or cobalamin, a micronutrient supplied by meat
and dairy products, is essential for mammalian intracellular
metabolism, particularly metabolism of one-carbon groups
and cell proliferation and differentiation (1, 2).
Low nutritional intake or impaired intestinal absorption of
vitamin B12 may lead to a negative balance and eventually
to functional deficiency when tissue storages are depleted.
Cobalamin deficiency has clinical consequences such as
megaloblastic anemia in severely deficient individuals, and
a variety of progressive neurological diseases that occur in
the absence of hematological complications, and hyperho-
mocysteinemia, associated with several pathological condi-
tions including cardiovascular diseases, birth defects,
neuropsychiatric disorders and dementia (3–5).
Determination of vitamin B12 concentrations is useful in
the prevention, diagnosis and/or prognosis of a variety of
disorders directly or indirectly associated with defects in the
metabolic pathways of this vitamin. However, serum total
vitamin B12 (tB12) concentrations are a dubious marker of
actual functional B12 status because in some cases it corre-
lates poorly with hematologic indices (6). Cobalamin defi-
ciency develops insidiously over the years, caused either by
an autoimmune disease, such as pernicious anemia, or due
to nutritional deficiency. Therefore, early and reliable diag-
nosis of vitamin B12 deficiency is essential because of the
latent nature of this disorder and the possible risk of irre-
versible neurological damage (7) which may be prevented
by vitamin supplementation.
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The determination of cobalamin status by measuring holo-
transcobalamin (HoloTC, or active B12) concentrations rep-
resents a new approach for diagnosing subtle cobalamin
deficiency (7, 8). HoloTC, the transcobalamin (TC)-cobala-
min complex representing the biologically active form of the
vitamin and consisting of ;10%–30% of total serum B12, is
recognized by ubiquitous specific membrane receptors (5, 7)
and could have high diagnostic value as a marker of storage
(5).
Several studies indicate that HoloTC is a more sensitive
marker of vitamin B12 status compared with total serum
cobalamin (5), and that it could be the earliest and most
sensitive marker for vitamin B12 deficiency (1). In fact,
HoloTC levels are low in most, but not all, patients with
biochemical signs of vitamin B12 deficiency. Notably, low
values have been reported in both vegetarians and vegans,
and in populations with a low intake of vitamin B12 (9–11).
According to some studies, there is enough evidence to
suggest that HoloTC is an early marker of changes in cobal-
amin homeostasis (12), and determination of a suitable
HoloTC cut-off point is essential due to the fact that the cut-
off threshold reported by different studies ranges from 35 to
45 pmol/L (13, 14).
The goals of this study were to evaluate the analytical
performance of this new immunoenzymatic method for
HoloTC (Active B12, Abbott Diagnostics, Wiesbaden, Ger-
many) using an automated analyzer (AxSYM, Abbott), and
to calculate an appropriate cut-off threshold for HoloTC that
would identify cobalamin deficiency in an Italian population.
Materials and methods
The active B12 immunoassay, based on a microparticle enzyme
immunoassay (MEIA) technique with calibration range of
0–128 pmol/L, was performed using the AxSYM analyzer (15).
Analytical performance was assessed using standard procedures.
Inter- and intra-assay imprecision were determined according to the
Clinical and Laboratory Standards Institute (CLSI) protocol EP5-
A2 (16) using a control sample that we prepared from pooled serum
(HoloTC concentration 76 pmol/L) and two levels of control
material supplied by the manufacturer (HoloTC concentration 23
pmol/L and 49 pmol/L).
Linearity was assessed by measuring samples prepared from
dilutions of two home-made serum pools containing high (143.3
pmol/L) and low (8.8 pmol/L) concentrations of HoloTC. Recovery
was assessed using 10 plasma samples containing known concen-
trations of HoloTC (range: 4.0–111.6 pmol/L) spiked with plasma
from a sample with a known HoloTC concentration (59.0 pmol/L).
Each aliquot was measured in duplicate and recovery was calculated
as the percentage of observed vs. the expected value.
The limit of detection was established by testing the assay cali-
brator A (0 pmol/L) 25 times and calculating the meanq2 SDs of
the measured results.
Possible correlation between HoloTC and the other diagnostic
parameters routinely used for vitamin B12 deficiency (tB12, folate,
homocysteine) was assessed using 250 routine blood specimens,
obtained from 107 men (mean age 59.0"18.8 years) and 143 wom-
en (mean age 54.2"23.1 years). The only inclusion criterion was
that the serum tB12 concentration be F221 pmol/L.
Each blood sample, collected in light protected tubes either
without additive for determining serum tB12, active B12, folate and
creatinine concentrations, or containing EDTA for plasma homo-
cysteine analysis, was tested fresh or stored at –808C until analysis.
To minimize analytical variation, a single technician assayed all
samples with the same instrument: serum tB12 and active B12 togeth-
er with serum folate concentrations using a MEIA (Abbott Diag-
nostics); plasma total homocysteine (tHcy) by a fluorescence
polarization immunoassay (FPIA, Abbott Diagnostics) with the
AxSYM analyzer. Measurement of serum creatinine was performed
using a colorimetric assay with the Modular analyzer (Roche Diag-
nostics, Basel, Switzerland).
Total B12 cut-off points were identified as those maximizing the
f correlation coefficient (TP•TN–FP•FN/(TPqFN)•(TNqFP)•
(TPqFP)•(TNqFN), where TPstrue positive, FPsfalse positive,
TNstrue negative and FNsfalse negative. The product yields a
number between y1 and 1, with 1 indicating a perfect prediction
and 0 random prediction. Values below 0 indicate worse than ran-
dom prediction. Next, HoloTC cut-off thresholds were derived and
the area under ROC curve (AUC), sensitivity and specificity were
calculated, along with their 95% confidence intervals (CI), estimat-
ed via bootstrap (1000 runs). All analyses were performed using the
R System (17).
Results
Mean analytical imprecision (intra-assay and inter-assay)
ranged between 2.9% and 4.1% CV for assay controls, and
between 6.0% and 7.7% CV for our home-made serum con-
trols. HoloTC linearity was confirmed for the range from 8.8
to 143.3 pmol/L (rs0.99). The assay mean recovery for
spiked specimens was 95% (interval: 90%–100%), and mean
linearity determined by dilution was 100% (interval:
93%–111%). The detection limit was 0.07 pmol/L.
Total B12 values maximizing the f correlation coefficient
were in the range of 138–186, with two local maxima, one
at 146 and another at 174. At these concentrations, the max-
imum f correlation coefficient was at 40 pmol/L HoloTC
(95% CI for f 0.225–0.283). Table 1 shows the AUC,
HoloTC sensitivity and specificity for the selected tB12 cut-
off thresholds.
HoloTC values were not affected by gender and age, and
estimated cut-off thresholds did not change according to age
and gender (p-value of the gender and age group difference
0.54 and 0.298, respectively).
The 250 serum specimens used for this study showed an
even distribution of tB12 values between the gray zone (GZ:
139–221 pmol/L; 126 subjects) and low values (L:
-139 pmol/L; 124 subjects). HoloTC mean concentrations
were 46.5"16.2 pmol/L in GZ and 34.2"14.0 pmol/L in L
samples (p-0.005). Moreover, the frequency of low HoloTC
value (-40 pmol/L) in subjects with low tB12 concentrations
was 68.2% compared to 37.9% in subjects with tB12 in GZ
(p-0.01).
Poor correlation was found between HoloTC and tB12, not
only in all 250 specimens (Rs0.420), but also in samples
with low values of tB12 only (Rs0.337).
No correlation was found between HoloTC and other para-
meters that are metabolically correlated to either tB12 (folate
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Table 1 AUC, HoloTC sensitivity and specificity for the selected tB12 cut-off thresholds.
tB12
-140 G140
HoloTC -40 104 96
G40 13 37
95% CI AUC 95% CI
Sens 0.74 0.62 0.86 Folate 0.61 0.47 0.75
Spec 0.52 0.38 0.66 Homocysteine 0.32 0.19 0.45
AUC 0.75 0.63 0.87 Creatinine 0.42 0.28 0.56
Left side: predictive capability of HoloTC at selected cut-off thresholds for total B12. Right side: areas under the ROC curve and 95% CIs
for other putative predictors. tB12, total B12; HoloTC, holotranscobalamin; Sens, sensitivity; Spec, specificity; AUC, area under ROC curve.
Table 2 Qualitative agreement between total B12 and HoloTC in 250 serum samples with total B12 -221 pmol/L.
Agreement 65.2% HoloTC Total
p-0.05
Normal Pathological
tB12 Normal 84 54 138
Pathological 33 79 112
Total 117 133 250
Pathological values were -139 pmol/L for total B12 and -40 pmol/L for HoloTC. tB12, total B12; HoloTC, holotranscobalamin.
and homocysteine) or creatinine. Linear regression analysis
showed correlation coefficients of 0.14, 0.14 and 0.10 for
folate, homocysteine and creatinine, respectively.
Qualitative agreement between HoloTC and tB12 was
65.2% (p-0.05). Interestingly, HoloTC and tB12 measured
in the 250 subjects identified 84 subjects with normal values
for both parameters and 79 with abnormal values for both
parameters. Additionally, tB12 values were low and HoloTC
concentrations were normal in 33 subjects, whereas 54 sub-
jects with normal values of total cobalamin (i.e., GZ) showed
low concentrations of HoloTC (Table 2).
Agreement of HoloTC with folate was 55.2% (p-0.0001),
with Hcy 51.6% (p-0.0001) and with creatinine 45.6%
(p-0.0001). These were lower than the agreement seen
between tB12 and these same parameters.
Discussion
There is concern about the feasibility of an early diagnosis
of cobalamin deficiency in asymptomatic subjects since the
prevalence of sub-clinical functional cobalamin deficiency is
higher than expected. Current assays measure serum tB12
concentration, a small percentage (10%–30%) of which,
HoloTC, is metabolically active (18). Recently, studies
focused on HoloTC to evaluate the potential reliability and
diagnostic usefulness of an active B12 assay for predicting
vitamin B12 status in different clinical settings (1, 2, 8, 10).
It is essential to establish a proper threshold point for active
B12 deficiency, as previous studies do not agree on cut-off
thresholds that range from 35 to 45 pmol/L.
We first checked the analytical performance of the assay,
which was good, and our data were comparable to those
obtained by Brady et al. (16). On the basis of our experi-
mental findings, the new AxSYM active B12 assay showed
good analytical reliability and ease of performance due to
the simple pre-analytical phase and complete automation of
the AxSYM analyzer, confirming the adequacy of the assay
for routine use.
The 40 pmol/L cut-off value we selected was also reported
by other authors (18–20). We also verified the predictive
ability of HoloTC at this threshold for selected tB12 cut-off
points. The AUC data were more predictive than other puta-
tive predictors of cobalamin deficiency such as folate and
Hcy.
The poor correlation between active B12 and tB12 values,
and the lack of correlation between HoloTC and the other
parameters that might be related to vitamin B12 status rep-
resents another relevant finding of this study. Our results con-
firm the suitability of the 40 pmol/L cut-off threshold for
assessing cobalamin deficiency in populations with reduced
tB12 values, showing a considerable percentage (53.2%) of
subjects with low levels of the most metabolically important
fraction of cobalamin.
Measurement of serum HoloTC concentration may prove
helpful in evaluating the absorption of vitamin B12 as
HoloTC concentrations and TC saturation reflect recent vita-
min B12 absorption better than serum tB12 (21). However,
according to Chen et al., HoloTC concentrations most prob-
ably reflect vitamin B12 status independently of its recent
absorption (22). Questions are still raised concerning the
specificity of the HoloTC assay. There is concern about sub-
tle cobalamin deficiency, especially in populations at risk.
As reported by Miller et al. (23) in a study of an elderly
cohort, and confirmed by Gonzalez-Gross et al. (24), meas-
urement of both HoloTC and tB12 concentrations provide
better screening for cobalamin deficiency than either assay
alone.
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The graded predictive classification of vitamin B12 defi-
ciency proposed by Miller et al. (23) showed that the meas-
urement of both parameters would help identify more at-risk
subjects. This classification may be used by physicians to
plan further diagnostic testing and/or treatment and in some
cases avoid over-treatment. In fact, as reported by Carmel et
al. (3), metabolic studies showed that not all the subjects
presenting with sub-clinical cobalamin insufficiency were
actually vitamin-deficient.
However, a recent study by Clarke et al. (18) showed that
using cut-off thresholds of equal sensitivity and specificity
(45 and 200 pmol/L for HoloTC and tB12, respectively),
HoloTC had slightly better diagnostic accuracy compared
with vitamin B12 in detecting actual vitamin B12 deficiency
in subjects with normal renal function, although neither test
can be recommended to screen asymptomatic individuals.
This is in contrast somewhat to an earlier study by our
group demonstrating the importance of HoloTC assay in
monitoring cobalamin status in asymptomatic subjects at risk
of developing sub-clinical vitamin B12 deficiency due to
some physio-pathological condition (e.g., elderly, obese sub-
jects) and/or life-style risk factor (e.g., smokers, vegans)
(25). Thus, accurate identification and reliable diagnosis of
vitamin B12 deficiency is important.
Finally, in agreement with Gonzalez-Gross’s observation
(24), and on the basis of our own experience, given the high
prevalence of hyperhomocysteinemia (frequently due to vita-
min B deficiency) careful monitoring of the metabolic mark-
ers of cobalamin status is suggested (26, 27).
In conclusion, determination of HoloTC concentrations
may be used as a complementary diagnostic strategy to avoid
the development of pathological conditions (macrocytic
anemia or neurological disease) before symptoms emerge,
and should also be used for large scale screening of subjects
at latent risk of cobalamin deficiency.
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